Liming Wu1,2,3, Zhe Yang1,2, Jie Zhang4, Haiyang Xie1,2, Lin Zhou1,2, Shusen Zheng1,2. 1. Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China. 2. Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310003, China. 3. Jingning National Hospital of the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China. 4. Department of Hepatobiliary Surgery, First Hospital of Jiaxing, Jiaxing University, Jiaxing 314000, China.
Abstract
BACKGROUND: The long noncoding RNA HOTTIP has recently been described as a biomarker of poor prognosis in patients with hepatocellular carcinoma (HCC). METHODS: In the present study, we evaluated the clinical significance of HOTTIP expression in predicting the rate of tumor recurrence in HCC patients after liver transplantation (LT). We examined the expression pattern and single nucleotide polymorphism (SNP) genotype of HOTTIP in HCC samples from 155 patients underwent LT, and its correlation with clinical parameters and patient prognosis was analyzed. HOTTIP was suppressed using siRNA to explore the role HOTTIP plays in tumor progression. RESULTS: The expression level of HOTTIP in cancer tissues was higher than in adjacent noncancerous tissues. Multivariate analyses revealed that HOTTIP expression was an independent prognostic factor for tumor recurrence and lower overall survival times in HCC patients after LT. Patients who beyond the Milan criteria and exhibit decreased HOTTIP expression experienced longer recurrence-free survival and overall survival. HOTTIP rs2071265 is associated with an earlier recurrence in HCC patients. Moreover, the suppression of HOTTIP in liver cancer cell lines reduced cell invasion rates and increased chemosensitivity. CONCLUSIONS: In summary, the high expression level of HOTTIP in HCC could serve as a candidate biomarker for predicting poor prognosis in HCC patients underwent liver transplant therapy. Furthermore, HOTTIP might be a potential therapeutic target.
BACKGROUND: The long noncoding RNA HOTTIP has recently been described as a biomarker of poor prognosis in patients with hepatocellular carcinoma (HCC). METHODS: In the present study, we evaluated the clinical significance of HOTTIP expression in predicting the rate of tumor recurrence in HCC patients after liver transplantation (LT). We examined the expression pattern and single nucleotide polymorphism (SNP) genotype of HOTTIP in HCC samples from 155 patients underwent LT, and its correlation with clinical parameters and patient prognosis was analyzed. HOTTIP was suppressed using siRNA to explore the role HOTTIP plays in tumor progression. RESULTS: The expression level of HOTTIP in cancer tissues was higher than in adjacent noncancerous tissues. Multivariate analyses revealed that HOTTIP expression was an independent prognostic factor for tumor recurrence and lower overall survival times in HCC patients after LT. Patients who beyond the Milan criteria and exhibit decreased HOTTIP expression experienced longer recurrence-free survival and overall survival. HOTTIP rs2071265 is associated with an earlier recurrence in HCC patients. Moreover, the suppression of HOTTIP in liver cancer cell lines reduced cell invasion rates and increased chemosensitivity. CONCLUSIONS: In summary, the high expression level of HOTTIP in HCC could serve as a candidate biomarker for predicting poor prognosis in HCC patients underwent liver transplant therapy. Furthermore, HOTTIP might be a potential therapeutic target.
Authors: L M Wu; F Zhang; H Y Xie; X Xu; Q X Chen; S Y Yin; X C Liu; L Zhou; X B Xu; Y L Sun; S S Zheng Journal: Clin Genet Date: 2008-01-03 Impact factor: 4.438
Authors: Marcel E Dinger; Paulo P Amaral; Tim R Mercer; Ken C Pang; Stephen J Bruce; Brooke B Gardiner; Marjan E Askarian-Amiri; Kelin Ru; Giulia Soldà; Cas Simons; Susan M Sunkin; Mark L Crowe; Sean M Grimmond; Andrew C Perkins; John S Mattick Journal: Genome Res Date: 2008-06-18 Impact factor: 9.043
Authors: F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts Journal: Hepatology Date: 2001-06 Impact factor: 17.425
Authors: Michael A Zimmerman; R Mark Ghobrial; Myron J Tong; Jonathan R Hiatt; Andrew M Cameron; Johnny Hong; Ronald W Busuttil Journal: Arch Surg Date: 2008-02
Authors: Vincenzo Mazzaferro; Josep M Llovet; Rosalba Miceli; Sherrie Bhoori; Marcello Schiavo; Luigi Mariani; Tiziana Camerini; Sasan Roayaie; Myron E Schwartz; Gian Luca Grazi; René Adam; Peter Neuhaus; Mauro Salizzoni; Jordi Bruix; Alejandro Forner; Luciano De Carlis; Umberto Cillo; Andrew K Burroughs; Roberto Troisi; Massimo Rossi; Giorgio E Gerunda; Jan Lerut; Jacques Belghiti; Ilka Boin; Jean Gugenheim; Fedja Rochling; Bart Van Hoek; Pietro Majno Journal: Lancet Oncol Date: 2008-12-04 Impact factor: 41.316